Capricor Therapeutics
CAPR
170 hedge funds and large institutions have $942M invested in Capricor Therapeutics in 2026 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 72 increasing their positions, 45 reducing their positions, and 35 closing their positions.
105% more call options, than puts
Call options by funds: $114M | Put options by funds: $55.8M
60% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 45
9.01% more ownership
Funds ownership: 58.82% → 67.82% (+9%)
4% less funds holding
Funds holding: 177 → 170 (-7)
8% less capital invested
Capital invested by funds: $1.03B → $942M (-$85.7M)
14% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 35
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$36.8M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
+$24.4M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$23.1M |
| 4 |
BlackRock
New York
|
+$21.9M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22M |
| 2 |
Jane Street
New York
|
-$17.2M |
| 3 |
JHC
Jones Hill Capital
New York
|
-$14.8M |
| 4 |
Barclays
London,
United Kingdom
|
-$7.5M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$6.08M |
CAPR Hedge Fund Activity: Q2 2026 in Review
170 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q2 2026, worth a combined $942M — down 8.3% from $1.03B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of CAPR and 30 opened new positions — a net loss of 5 holders — while 45 trimmed existing stakes and 72 added.
The largest buyer was State Street, adding an estimated $36.8M. The largest seller was Point72 Asset Management, cutting an estimated $22M.
- 170 institutional investors held Capricor Therapeutics (CAPR) as of Q2 2026, down from 177 in Q1 2026.
- Funds reported $942M of Capricor Therapeutics stock for Q2 2026, down 8.3% quarter-over-quarter.
- 30 funds opened new Capricor Therapeutics positions in Q2 2026 and 35 closed out, a net change of -5 holders.
- The largest Capricor Therapeutics buyer in Q2 2026 was State Street, an estimated $36.8M added.
- The largest Capricor Therapeutics seller in Q2 2026 was Point72 Asset Management, an estimated $22M sold.
Based on aggregated 13F filings for Q2 2026.